COL1A2 and pulmonary fibrosis: In contrast, tamoxifen-injected Bosutinib-treated TBRIca-Col1a2-Cre mice (Fig 1B) displayed a dose-dependent decrease in pulmonary fibrosis and alveolar/parenchymal abnormalities compared with animals injected with tamoxifen alone.